Erythromycin markedly increases bromocriptine
plasma levels (by more than 4-fold), and a case of
toxicity has been reported. Bromocriptine
toxicity has also occurred in a patient given josamycin. Clarithromycin increases the bioavailability of
cabergoline by about 2- to 4-fold.
Concurrent use should be well monitored if
macrolides that affect CYP3A4 are given (e.g.
clarithromycin,
erythromycin,
telithromycin, see
macrolides, for further details). It has been suggested that the bromocriptine dose may need to be reduced by 50% to avoid
toxicity.